Discussion about this post

User's avatar
Iain Noble's avatar

I watched it yesterday and is was very good.

Expand full comment
Florida ER Doc's avatar

Excellent discussion! Like Dr. B, Dr. Kulldorff is worthy of great admiration and respect. History will look back on him as one of a small group of scientists who were brave enough to speak out and tell the truth in the face of almost unspeakable derision and enmity. One point I disagree with, however, is his attitude and reflection on the J & J vaccine pause. While I agree with some of his points in his 4/21 opinion piece in the Hill (i.e. that there shouldn't have been a pause for at-risk elderly patients), I feel that he doesn't give proper weight to the risks to young healthy individuals. In the piece, he notes the oft-repeated statistic of 1/1,000.000 in regard to the CVST risk in those receiving the J & J vaccine. I have a very hard time believing that figure, given that there was a case of CVST in the original J & J study. A healthy 25 yo male suffered a transverse sinus thrombosis shortly after receiving the vaccine. Incredibly, this event was deemed "not related to therapy". The PI's explanation strains credulity:

"Event most likely resulted from multiple pre-disposing factors including pre-existing cerebral sigmoid sinus stenosis that pre-disposed the participant to cerebral venous thrombosis, and an infection with an unknown organism that started 8 days following vaccination, triggering inflammation and a hypercoagulable state. Thrombocytopenia also observed. Subsequent testing identified anti-PF4 antibodies at the time of the event."

If the risk is 1/1.000.000, what is the likelihood of finding a case in 22,000 participants in the vaccine arm? In my humble opinion, the risk benefit ratio for the use of this vaccine (as well as for the mRNA vaccines) never made sense for young healthy people.

https://www.nejm.org/doi/suppl/10.1056/NEJMoa2101544/suppl_file/nejmoa2101544_appendix.pdf

p.50

Expand full comment
9 more comments...

No posts